Skip to main content

MYRIAD GENETICS INC

For the period ended Mar 31, 2024. Filed May 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 1. Financial Statements

Condensed Consolidated Balance Sheets

March 31,2024December 31,2023
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents$96.9$132.1
Marketable investment securities7.48.8
Trade accounts receivable118.1114.3
Inventory24.622.0
Prepaid taxes18.417.0
Prepaid expenses and other current assets24.919.4
Total current assets290.3313.6
Operating lease right-of-use assets58.961.6
Property, plant, and equipment, net118.5119.0
Intangibles, net340.9349.5
Goodwill287.0287.4
Other assets14.915.4
Total assets$1,110.5$1,146.5
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$33.1$25.8
Accrued liabilities99.2113.9
Current maturities of operating lease liabilities13.816.2
Total current liabilities146.1155.9
Unrecognized tax benefits30.830.2
Long-term debt38.738.5
Noncurrent operating lease liabilities94.397.4
Other long-term liabilities40.641.3
Total liabilities350.5363.3
Commitments and contingencies
Stockholders’ equity:
Common stock, 90.5 million and 89.9 million shares outstanding at March 31, 2024 and December 31, 2023, respectively0.90.9
Additional paid-in capital1,418.81,415.5
Accumulated other comprehensive loss(4.2)(3.7)
Accumulated deficit(655.5)(629.5)
Total stockholders' equity760.0783.2
Total liabilities and stockholders’ equity$1,110.5$1,146.5
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.